The global Non-alcoholic Steatohepatitis market size was valued at USD 2605.3 million in 2023 and is forecast to a readjusted size of USD 9170.5 million by 2030 with a CAGR of 19.7% during review period.
Non-alcoholic steatohepatitis听(NASH) is an advanced form of听non-alcoholic fatty liver disease听(NAFLD). NAFLD is caused by buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver.
NASH is a progressive liver disease characterized by fat accumulation in the liver, inflammation, and liver cell damage, typically occurring in individuals who do not consume excessive alcohol. Several factors are driving the growth of the NASH market. Firstly, the rising prevalence of obesity and metabolic disorders, such as diabetes and dyslipidemia, is contributing to the increasing incidence of NASH. Unhealthy lifestyles, sedentary habits, and poor dietary choices are leading to a higher risk of developing NASH, creating a substantial patient population in need of diagnosis and treatment. Secondly, the improved understanding and awareness of NASH among healthcare professionals and the general population have resulted in increased diagnosis rates. As the medical community recognizes the long-term complications and progression of NASH, there is a greater emphasis on identifying patients with NASH and implementing appropriate management strategies.
This report includes an overview of the development of the Non-alcoholic Steatohepatitis industry chain, the market status of Oral (Solid, Liquid), Parenteral (Solid, Liquid), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Non-alcoholic Steatohepatitis.
Regionally, the report analyzes the Non-alcoholic Steatohepatitis markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Non-alcoholic Steatohepatitis market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Non-alcoholic Steatohepatitis market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Non-alcoholic Steatohepatitis industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Solid, Liquid).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Non-alcoholic Steatohepatitis market.
Regional Analysis: The report involves examining the Non-alcoholic Steatohepatitis market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Non-alcoholic Steatohepatitis market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Non-alcoholic Steatohepatitis:
Company Analysis: Report covers individual Non-alcoholic Steatohepatitis players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Non-alcoholic Steatohepatitis This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Oral, Parenteral).
Technology Analysis: Report covers specific technologies relevant to Non-alcoholic Steatohepatitis. It assesses the current state, advancements, and potential future developments in Non-alcoholic Steatohepatitis areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Non-alcoholic Steatohepatitis market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Non-alcoholic Steatohepatitis market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Solid
Liquid
麻豆原创 segment by Application
Oral
Parenteral
麻豆原创 segment by players, this report covers
AstraZeneca
Pfizer
GSK
Novo Nordisk
Roche
AbbVie
Galectin Therapeutics
Galmed Pharmaceuticals
Gilead
Intercept pharma
Non-alcoholic Steatohepatitis
Takeda
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Non-alcoholic Steatohepatitis product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Non-alcoholic Steatohepatitis, with revenue, gross margin and global market share of Non-alcoholic Steatohepatitis from 2019 to 2024.
Chapter 3, the Non-alcoholic Steatohepatitis competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Non-alcoholic Steatohepatitis market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Non-alcoholic Steatohepatitis.
Chapter 13, to describe Non-alcoholic Steatohepatitis research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope of Non-alcoholic Steatohepatitis
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Non-alcoholic Steatohepatitis by Type
1.3.1 Overview: Global Non-alcoholic Steatohepatitis 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Non-alcoholic Steatohepatitis Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Solid
1.3.4 Liquid
1.4 Global Non-alcoholic Steatohepatitis 麻豆原创 by Application
1.4.1 Overview: Global Non-alcoholic Steatohepatitis 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Oral
1.4.3 Parenteral
1.5 Global Non-alcoholic Steatohepatitis 麻豆原创 Size & Forecast
1.6 Global Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast by Region
1.6.1 Global Non-alcoholic Steatohepatitis 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Non-alcoholic Steatohepatitis 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Non-alcoholic Steatohepatitis 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Non-alcoholic Steatohepatitis 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Non-alcoholic Steatohepatitis 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Non-alcoholic Steatohepatitis 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Non-alcoholic Steatohepatitis 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Non-alcoholic Steatohepatitis Product and Solutions
2.1.4 AstraZeneca Non-alcoholic Steatohepatitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Non-alcoholic Steatohepatitis Product and Solutions
2.2.4 Pfizer Non-alcoholic Steatohepatitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Pfizer Recent Developments and Future Plans
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Non-alcoholic Steatohepatitis Product and Solutions
2.3.4 GSK Non-alcoholic Steatohepatitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 GSK Recent Developments and Future Plans
2.4 Novo Nordisk
2.4.1 Novo Nordisk Details
2.4.2 Novo Nordisk Major Business
2.4.3 Novo Nordisk Non-alcoholic Steatohepatitis Product and Solutions
2.4.4 Novo Nordisk Non-alcoholic Steatohepatitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Novo Nordisk Recent Developments and Future Plans
2.5 Roche
2.5.1 Roche Details
2.5.2 Roche Major Business
2.5.3 Roche Non-alcoholic Steatohepatitis Product and Solutions
2.5.4 Roche Non-alcoholic Steatohepatitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Roche Recent Developments and Future Plans
2.6 AbbVie
2.6.1 AbbVie Details
2.6.2 AbbVie Major Business
2.6.3 AbbVie Non-alcoholic Steatohepatitis Product and Solutions
2.6.4 AbbVie Non-alcoholic Steatohepatitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 AbbVie Recent Developments and Future Plans
2.7 Galectin Therapeutics
2.7.1 Galectin Therapeutics Details
2.7.2 Galectin Therapeutics Major Business
2.7.3 Galectin Therapeutics Non-alcoholic Steatohepatitis Product and Solutions
2.7.4 Galectin Therapeutics Non-alcoholic Steatohepatitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Galectin Therapeutics Recent Developments and Future Plans
2.8 Galmed Pharmaceuticals
2.8.1 Galmed Pharmaceuticals Details
2.8.2 Galmed Pharmaceuticals Major Business
2.8.3 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Product and Solutions
2.8.4 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Galmed Pharmaceuticals Recent Developments and Future Plans
2.9 Gilead
2.9.1 Gilead Details
2.9.2 Gilead Major Business
2.9.3 Gilead Non-alcoholic Steatohepatitis Product and Solutions
2.9.4 Gilead Non-alcoholic Steatohepatitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Gilead Recent Developments and Future Plans
2.10 Intercept pharma
2.10.1 Intercept pharma Details
2.10.2 Intercept pharma Major Business
2.10.3 Intercept pharma Non-alcoholic Steatohepatitis Product and Solutions
2.10.4 Intercept pharma Non-alcoholic Steatohepatitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Intercept pharma Recent Developments and Future Plans
2.11 Non-alcoholic Steatohepatitis
2.11.1 Non-alcoholic Steatohepatitis Details
2.11.2 Non-alcoholic Steatohepatitis Major Business
2.11.3 Non-alcoholic Steatohepatitis Non-alcoholic Steatohepatitis Product and Solutions
2.11.4 Non-alcoholic Steatohepatitis Non-alcoholic Steatohepatitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Non-alcoholic Steatohepatitis Recent Developments and Future Plans
2.12 Takeda
2.12.1 Takeda Details
2.12.2 Takeda Major Business
2.12.3 Takeda Non-alcoholic Steatohepatitis Product and Solutions
2.12.4 Takeda Non-alcoholic Steatohepatitis Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 Takeda Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Non-alcoholic Steatohepatitis Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Non-alcoholic Steatohepatitis by Company Revenue
3.2.2 Top 3 Non-alcoholic Steatohepatitis Players 麻豆原创 Share in 2023
3.2.3 Top 6 Non-alcoholic Steatohepatitis Players 麻豆原创 Share in 2023
3.3 Non-alcoholic Steatohepatitis 麻豆原创: Overall Company Footprint Analysis
3.3.1 Non-alcoholic Steatohepatitis 麻豆原创: Region Footprint
3.3.2 Non-alcoholic Steatohepatitis 麻豆原创: Company Product Type Footprint
3.3.3 Non-alcoholic Steatohepatitis 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Non-alcoholic Steatohepatitis Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Non-alcoholic Steatohepatitis 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Non-alcoholic Steatohepatitis Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Non-alcoholic Steatohepatitis 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Non-alcoholic Steatohepatitis Consumption Value by Type (2019-2030)
6.2 North America Non-alcoholic Steatohepatitis Consumption Value by Application (2019-2030)
6.3 North America Non-alcoholic Steatohepatitis 麻豆原创 Size by Country
6.3.1 North America Non-alcoholic Steatohepatitis Consumption Value by Country (2019-2030)
6.3.2 United States Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Non-alcoholic Steatohepatitis Consumption Value by Type (2019-2030)
7.2 Europe Non-alcoholic Steatohepatitis Consumption Value by Application (2019-2030)
7.3 Europe Non-alcoholic Steatohepatitis 麻豆原创 Size by Country
7.3.1 Europe Non-alcoholic Steatohepatitis Consumption Value by Country (2019-2030)
7.3.2 Germany Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Non-alcoholic Steatohepatitis Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Non-alcoholic Steatohepatitis Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Non-alcoholic Steatohepatitis 麻豆原创 Size by Region
8.3.1 Asia-Pacific Non-alcoholic Steatohepatitis Consumption Value by Region (2019-2030)
8.3.2 China Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Non-alcoholic Steatohepatitis Consumption Value by Type (2019-2030)
9.2 South America Non-alcoholic Steatohepatitis Consumption Value by Application (2019-2030)
9.3 South America Non-alcoholic Steatohepatitis 麻豆原创 Size by Country
9.3.1 South America Non-alcoholic Steatohepatitis Consumption Value by Country (2019-2030)
9.3.2 Brazil Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Non-alcoholic Steatohepatitis Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Non-alcoholic Steatohepatitis Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Non-alcoholic Steatohepatitis 麻豆原创 Size by Country
10.3.1 Middle East & Africa Non-alcoholic Steatohepatitis Consumption Value by Country (2019-2030)
10.3.2 Turkey Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Non-alcoholic Steatohepatitis 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Non-alcoholic Steatohepatitis 麻豆原创 Drivers
11.2 Non-alcoholic Steatohepatitis 麻豆原创 Restraints
11.3 Non-alcoholic Steatohepatitis Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Non-alcoholic Steatohepatitis Industry Chain
12.2 Non-alcoholic Steatohepatitis Upstream Analysis
12.3 Non-alcoholic Steatohepatitis Midstream Analysis
12.4 Non-alcoholic Steatohepatitis Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
AstraZeneca
Pfizer
GSK
Novo Nordisk
Roche
AbbVie
Galectin Therapeutics
Galmed Pharmaceuticals
Gilead
Intercept pharma
Non-alcoholic Steatohepatitis
Takeda
听
听
*If Applicable.
